```html

Viral Hepatitis C – Comprehensive Medical Guide

Overview

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). It is spread primarily through blood-to‑blood contact. Unlike hepatitis A and B, most people with acute infection are asymptomatic, and the disease often becomes chronic, leading to long‑term liver damage.

• Global prevalence: According to the World Health Organization (WHO), about 58 million people worldwide have chronic HCV infection, and ~1.5 million new infections occur each year.
• U.S. statistics: The CDC estimates roughly 2.4 million Americans are living with hepatitis C, with the highest rates in adults aged 40‑69.
• Who it affects: Anyone can acquire HCV, but risk is higher among people who inject drugs, recipients of unscreened blood products, and those with long‑term dialysis.

Symptoms

Symptoms differ between the acute phase (first 6 months) and chronic infection.

Acute Hepatitis C (often silent)

• Fever, fatigue, muscle aches
• Loss of appetite, nausea, vomiting
• Jaundice (yellowing of skin/eyes)
• Dark urine and pale stools
• Right‑upper‑quadrant abdominal pain

Chronic Hepatitis C (develops in ~75 % of infections)

• Persistent fatigue and weakness
• Gradual weight loss
• Persistent right‑upper‑quadrant discomfort
• Mild jaundice (often absent)
• Joint and muscle aches
• Skin changes: itching, spider angiomas, or a condition called lichen planus
• Depression or cognitive “brain fog”

Because many people remain asymptomatic for years, routine screening is crucial, especially for those with known risk factors.

Causes and Risk Factors

HCV is a single‑stranded RNA virus that infects hepatocytes (liver cells). It is highly resilient in the environment, surviving outside the body for up to 3 weeks.

Primary modes of transmission

• Sharing needles or other injection equipment (the most common route in high‑income countries)
• Receiving blood transfusions or organ transplants before 1992 (when routine screening began in many nations)
• Occupational exposure to contaminated blood (health‑care workers)
• Mother‑to‑child transmission (≈5 % risk if the mother is HCV‑positive)
• Percutaneous exposure during tattooing, piercing, or body‑modification with non‑sterile tools

Risk factors that increase likelihood of infection

• History of injection drug use (IDU)
• Being on long‑term hemodialysis
• HIV infection (co‑infection worsens outcomes)
• History of incarceration
• Living in regions with high HCV prevalence (e.g., parts of Egypt, Central and East Asia)
• Unprotected sexual activity with an HCV‑positive partner, especially among men who have sex with men (MSM) who also have HIV

Diagnosis

Diagnosing HCV involves a two‑step approach: screening for antibodies, then confirming active infection with viral RNA testing.

1. Antibody screening (anti‑HCV)

• Enzyme‑linked immunosorbent assay (ELISA) or rapid point‑of‑care tests.
• A positive result indicates exposure at some point, but not necessarily current infection.

2. Confirmatory testing

• HCV RNA PCR (polymerase chain reaction): Detects viral genetic material; a positive result confirms active infection.
• Quantitative viral load: Measures the amount of virus (IU/mL) and guides treatment decisions.

3. Genotyping

HCV exists in at least 7 genotypes (1‑7) and multiple subtypes. Genotype influences treatment length and drug choice, although newer pan‑genotypic regimens reduce this dependence.

4. Assessing liver disease severity

• Blood‑based fibrosis scores (e.g., APRI, FIB‑4)
• Transient elastography (FibroScan) – non‑invasive measurement of liver stiffness.
• Liver biopsy – rarely needed now, reserved for ambiguous cases.

Screening recommendations

The CDC and USPSTF advise one‑time HCV screening for all adults aged 18‑79, and periodic testing for people with ongoing risk (e.g., injection drug users).

Treatment Options

Since 2014, direct‑acting antiviral (DAA) regimens have transformed hepatitis C therapy. They achieve cure rates >95 % with minimal side effects and short treatment courses (8‑12 weeks).

First‑line DAAs (pan‑genotypic)

• Sofosbuvir/Velpatasvir (Epclusa): 12‑week course for most genotypes; extends to 24 weeks for decompensated cirrhosis.
• Glecaprevir/Pibrentasvir (Mavyret): 8‑week regimen for treatment‑naïve patients without cirrhosis; 12‑weeks for those with compensated cirrhosis.

Alternative regimens (genotype‑specific)

• Sofosbuvir/Ledipasvir (Harvoni) – mainly genotype 1, 4, 5, 6.
• Elbasvir/Grazoprevir (Zepatier) – genotype 1, 4, 6.

Adjunctive considerations

• Assess for drug‑drug interactions—many DAAs are metabolized by CYP3A4.
• Manage co‑infections (HIV, HBV). Treat HBV first or start prophylaxis because DAAs can reactivate HBV.
• For patients with advanced liver disease, close monitoring for decompensation is required.

Lifestyle & supportive measures

• Avoid alcohol – it accelerates fibrosis.
• Maintain a healthy weight; manage diabetes and hyperlipidemia.
• Vaccinate against hepatitis A and B if not immune.
• Adhere strictly to medication schedule; missed doses reduce cure rates.

Living with Viral Hepatitis C

Even after a cure (sustained virologic response, SVR), ongoing liver health monitoring is essential, especially for those with prior cirrhosis.

Daily management tips

• Medication adherence: Use pillboxes or smartphone reminders.
• Regular follow‑up: Labs at baseline, end of treatment, and 12 weeks post‑treatment to confirm SVR.
• Alcohol moderation: Zero tolerance is best for patients with any fibrosis.
• Nutrition: Emphasize a Mediterranean‑style diet rich in fruits, vegetables, whole grains, lean protein, and healthy fats.
• Physical activity: Aim for ≥150 minutes of moderate‑intensity aerobic exercise per week.
• Mental health: Screen for depression or anxiety; HCV has been linked to neurocognitive changes.
• Stay up‑to‑date on vaccinations: Hepatitis A, B, influenza, COVID‑19, pneumococcal.

After SVR

Patients without prior cirrhosis generally return to normal life expectancy. Those with advanced fibrosis or cirrhosis require lifelong surveillance for hepatocellular carcinoma (HCC) every 6‑12 months with ultrasound ± alpha‑fetoprotein.

Prevention

Because no vaccine exists for HCV, prevention focuses on interrupting transmission pathways.

• Safe injection practices: Use sterile needles for each use; consider needle‑exchange programs.
• Screen blood products: All donated blood is screened in high‑income countries; remain cautious in low‑resource settings.
• Medical safety: Health‑care facilities should follow universal precautions (gloves, proper sharps disposal).
• Body‑modification hygiene: Choose licensed tattoo/piercing studios that use single‑use needles and sterilized equipment.
• Sexual health: Use condoms, especially with multiple partners or if coinfected with HIV.
• Mother‑to‑child: Antiviral treatment before or during pregnancy can reduce vertical transmission; discuss options with obstetrician.
• Testing: Encourage at‑risk individuals to get screened; early diagnosis improves outcomes.

Complications

If left untreated, chronic hepatitis C can lead to serious liver disease and extra‑hepatic manifestations.

• Cirrhosis: Develops in 15‑30 % of chronic infections after 20‑30 years.
• Hepatocellular carcinoma (HCC): Risk rises to 1‑4 % per year in cirrhotic patients.
• Decompensated liver disease: Ascites, variceal bleeding, hepatic encephalopathy.
• Mixed cryoglobulinemia: Immune complex vasculitis causing skin lesions, kidney disease.
• Renal disease: Membranoproliferative glomerulonephritis.
• Insulin resistance & type 2 diabetes.
• Cardiovascular disease: Higher rates of atherosclerosis.
• Neurocognitive disorders: “Hepatitis C‑associated neurocognitive disorder” (HCAND).

When to Seek Emergency Care

---

Sources: World Health Organization (WHO). Hepatitis C Fact Sheet 2022; Centers for Disease Control and Prevention (CDC). “Hepatitis C FAQs.” 2023; Mayo Clinic. “Hepatitis C Treatment.” 2024; American Association for the Study of Liver Diseases (AASLD) Guidelines 2023; Cleveland Clinic. “Hepatitis C Overview.” 2023; National Institutes of Health (NIH) LiverTox Database.

```